Which radiation boost is better for prostate cancer? new trial aims to find out

NCT ID NCT01936883

Ongoing Disease control Sponsor: British Columbia Cancer Agency Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This trial compares two types of brachytherapy boost (HDR vs LDR) given alongside external beam radiation for intermediate- and high-risk prostate cancer. The goal is to see which one provides better cancer control and quality of life with fewer side effects. About 195 men are taking part, and researchers are tracking their urinary, bowel, and sexual function over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation (brachytherapy boost)
What this could lead to: If HDR brachytherapy works better, it could offer similar cancer control with fewer side effects and better quality of life for men with prostate cancer.
What could go wrong: This is a mid-sized trial (195 people) comparing two established treatments, so major breakthroughs are unlikely. Results may not apply to all prostate cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

British Columbia Cancer Agency Center for the Southern Interior

Kelowna, British Columbia, V1Y5L3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.